Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is…
Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent…
STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…
24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profileOngoing registrational…
VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience…
The growth of the Mindfulness Meditation Apps Market is primarily driven by rising global awareness of mental health and wellness,…
HITRUST certification validates FCS is operating leading security practices to protect sensitive information. FORT MYERS, Fla., Oct. 8, 2025 /PRNewswire/…
New Chief of Staff, Medical Director and VP of Product join executive team to unite clinical expertise, AI innovation, and…
Trial will identify response and predictive biomarkers for the combination of BND-22, a first-in-class anti-ILT2 antibody with anti-PD1 therapy MISGAV,…